| Not Yet Recruiting | Association Between Chronic Psychological Stress and Disease Course Outcomes in Pancreatic Cancer NCT07529626 | Shanghai Zhongshan Hospital | — |
| Not Yet Recruiting | Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resecta NCT07469956 | Sun Yat-sen University | Phase 2 |
| Not Yet Recruiting | Open-Label, Phase 1 Clinical Trial of Neoadjuvant Nogapendekin Alfa Inbakicept, Sotevtamab, and Zabadinostat i NCT07488884 | ImmunityBio, Inc. | Phase 1 |
| Not Yet Recruiting | Neoadjuvant Chemotherapy for Elderly with Pancreatic Head Cancer NCT06868693 | Azienda Unita Sanitaria Locale di Piacenza | — |
| Active Not Recruiting | Construction of a Predictive Model for the Efficacy of Chemoprevention Combined With Targeted Therapy in Pancr NCT07326150 | Zhejiang Cancer Hospital | — |
| Not Yet Recruiting | Neoadjuvant Treatment vs Upfront Surgery for Left-Sided Pancreatic Cancer NCT07155629 | Helsinki University Central Hospital | Phase 3 |
| Recruiting | Neoadjuvant vs Upfront Surgery for Resectable Pancreatic Cancer and Periampullary Cancer NCT07081360 | Minia University | Phase 3 |
| Not Yet Recruiting | Evaluate the Clinical Feasibility of a Novel Neoantigen-Reactive CD8+ T Cell (NART) Detection Technology for P NCT06941987 | Shanghai Zhongshan Hospital | — |
| Not Yet Recruiting | Personalized Tumor Neoantigen MRNA Therapy Adjuvant Treatment for Postoperative Pancreatic Cancer. NCT06888674 | Zhejiang University | Phase 1 / Phase 2 |
| Recruiting | Antecolic Versus Retrocolic Gastrojejunostomy During Whipple's Procedure NCT06914349 | University of Thessaly | N/A |
| Recruiting | Optimal Perioperative Pain Control in Minimally Invasive Abdominal Cancer Surgery NCT06731998 | Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) | N/A |
| Not Yet Recruiting | Conventional Partial Pancreatoduodenectomy Versus an Extended Pancreatoduodenectomy for Pancreatic Head Cancer NCT06703905 | First Affiliated Hospital Xi'an Jiaotong University | N/A |
| Recruiting | Oncological Safety of Spleen Preservation in Left Pancreatectomy for Pancreatic Ductal Adenocarcinoma (SPLENDI NCT07157605 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | — |
| Recruiting | Study of Adjuvant Nimotuzumab Combined with Nab-paclitaxel+ Gemcitabine in EGFR-positive Pancreatic Cancer NCT06722911 | Zhejiang Provincial People's Hospital | Phase 2 |
| Not Yet Recruiting | Spanish Registry of Quality Indicators and Adverse Events of Endoscopic Retrograde Cholangiopancreatography NCT06670547 | Germans Trias i Pujol Hospital | — |
| Not Yet Recruiting | Early Diagnosis of Pancreatic Cancer Via Deciphering Multi-modal Immunological Signatures NCT06495749 | Zhejiang University | — |
| Recruiting | Clinical Study of mRNA Vaccine Combined With PD-1 Inhibitor as Adjuvant Therapy for Postoperative Pancreatic C NCT06496373 | Ruijin Hospital | EARLY_Phase 1 |
| Recruiting | The Study of Huaier Granule in Postoperative Adjuvant Therapy of Resectable Pancreatic Cancer NCT06368063 | Xi'an Jiaotong University | Phase 4 |
| Not Yet Recruiting | EUS-guided Choledochoduodenostomy vs ERCP as First Line in Malignant Distal Obstruction in Resectable Disease NCT06375928 | Hospital Universitari de Bellvitge | N/A |
| Not Yet Recruiting | Perioperative Platelet Inhibition With Acetylsalicylic Acid in Patients With Resectable Tumors of the Pancreat NCT05637567 | German Cancer Research Center | Phase 2 |
| Recruiting | French Assessment of MRD by Liquid Biopsies in PDAC Patients (FRENCH.MRD.PDAC) NCT06287749 | University Hospital, Montpellier | — |
| Completed | Frailty Scales for Predicting Chemotherapy Toxicity in Older Adults With Gastrointestinal Cancers NCT07184047 | Ankara Etlik City Hospital | — |
| Active Not Recruiting | ctDNA-based Minimal Residual Disease Detection for Resected Pancreatic Adenocarcinoma NCT05479708 | BAIYONG SHEN | — |
| Recruiting | Pancreatic Cancer Detection Consortium NCT06388967 | City of Hope Medical Center | — |
| Unknown | Survival Analysis After Neoadjuvant Therapy in Patients With Resectable Pancreatic Cancer and Risk Factors NCT05181605 | Instituto de investigación e innovación biomédica de Cádiz | Phase 2 / Phase 3 |
| Unknown | Clinical Trial to Evaluate the Safety and Efficacy of IM96 CAR-T Cells Therapy in Patients With Advanced Diges NCT05287165 | Beijing Immunochina Medical Science & Technology Co., Ltd. | EARLY_Phase 1 |
| Unknown | Development of a Prediction Platform for Adjuvant Treatment and Prognosis in Resected Pancreatic Cancer Using NCT04736043 | Samsung Medical Center | — |
| Completed | Efficacy and Safety of mFOLFIRINOX as Postoperative Chemotherapy for Pancreatic Cancer in Chinese Patients. NCT04224402 | Yuhong Li | Phase 2 |
| Recruiting | Effect of an Enhanced Recovery After Surgery Program on Outcomes After Pancreatoduodenectomy NCT06935448 | University of Thessaly | — |
| Recruiting | Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer NCT03977233 | UNC Lineberger Comprehensive Cancer Center | Phase 2 |
| Completed | Molecular Subtyping for Prognosis Evaluation in Resected Pancreatic Adenocarcinoma NCT05483257 | BAIYONG SHEN | — |
| Terminated | Pre-Operative Trial (PGHA vs. PGH) for Resectable Pancreatic Cancer NCT03344172 | Nathan Bahary, MD | Phase 2 |
| Completed | Investigation of the Optimal Duration of Neoadjuvant Therapy for Resectable Pancreatic Cancer NCT06809374 | Kochi University | — |